Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in Generalized Myasthenia Gravis
NCT07622342Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2173 in myasthenia gravis (MG), sponsored by Hengrui Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
SHR-2173
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07622342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622342.